| Genome-scale CRISPR-Cas9 knockout screening in human cells O Shalem, NE Sanjana, E Hartenian, X Shi, DA Scott, TS Mikkelsen, ... Science 343 (6166), 84-87, 2014 | 5569 | 2014 |
| Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 JG Doench, N Fusi, M Sullender, M Hegde, EW Vaimberg, KF Donovan, ... Nature biotechnology 34 (2), 184-191, 2016 | 3895 | 2016 |
| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2614 | 2017 |
| Specificity of microRNA target selection in translational repression JG Doench, PA Sharp Genes & development 18 (5), 504-511, 2004 | 2222 | 2004 |
| siRNAs can function as miRNAs JG Doench, CP Petersen, PA Sharp Genes & development 17 (4), 438-442, 2003 | 1853 | 2003 |
| Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation JG Doench, E Hartenian, DB Graham, Z Tothova, M Hegde, I Smith, ... Nature biotechnology 32 (12), 1262-1267, 2014 | 1775 | 2014 |
| Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway VS Viswanathan, MJ Ryan, HD Dhruv, S Gill, OM Eichhoff, ... Nature 547 (7664), 453-457, 2017 | 1422 | 2017 |
| In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target RT Manguso, HW Pope, MD Zimmer, FD Brown, KB Yates, BC Miller, ... Nature 547 (7664), 413-418, 2017 | 1013 | 2017 |
| Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ... Cancer cell 24 (6), 777-790, 2013 | 823 | 2013 |
| A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing D Pan, A Kobayashi, P Jiang, L Ferrari de Andrade, RE Tay, AM Luoma, ... Science 359 (6377), 770-775, 2018 | 728 | 2018 |
| Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities KR Sanson, RE Hanna, M Hegde, KF Donovan, C Strand, ME Sullender, ... Nature communications 9 (1), 5416, 2018 | 691 | 2018 |
| A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis Y Zou, MJ Palte, AA Deik, H Li, JK Eaton, W Wang, YY Tseng, R Deasy, ... Nature communications 10 (1), 1617, 2019 | 588 | 2019 |
| Discovering the anticancer potential of non-oncology drugs by systematic viability profiling SM Corsello, RT Nagari, RD Spangler, J Rossen, M Kocak, JG Bryan, ... Nature cancer 1 (2), 235-248, 2020 | 541 | 2020 |
| Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade JJ Ishizuka, RT Manguso, CK Cheruiyot, K Bi, A Panda, A Iracheta-Vellve, ... Nature 565 (7737), 43-48, 2019 | 517 | 2019 |
| Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis Y Zou, H Li, ET Graham, AA Deik, JK Eaton, W Wang, G Sandoval-Gomez, ... Nature chemical biology 16 (3), 302-309, 2020 | 488 | 2020 |
| Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection J Wei, MM Alfajaro, PC DeWeirdt, RE Hanna, WJ Lu-Culligan, WL Cai, ... Cell 184 (1), 76-91. e13, 2021 | 453 | 2021 |
| Mutational processes shape the landscape of TP53 mutations in human cancer AO Giacomelli, X Yang, RE Lintner, JM McFarland, M Duby, J Kim, ... Nature genetics 50 (10), 1381-1387, 2018 | 410 | 2018 |
| Am I ready for CRISPR? A user's guide to genetic screens JG Doench Nature Reviews Genetics 19 (2), 67-80, 2018 | 390 | 2018 |
| Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy J Wei, L Long, W Zheng, Y Dhungana, SA Lim, C Guy, Y Wang, YD Wang, ... Nature 576 (7787), 471-476, 2019 | 295 | 2019 |
| A genome-wide CRISPR death screen identifies genes essential for oxidative phosphorylation JD Arroyo, AA Jourdain, SE Calvo, CA Ballarano, JG Doench, DE Root, ... Cell metabolism 24 (6), 875-885, 2016 | 295 | 2016 |
David E. RootBroad Institute在 broadinstitute.org 的电子邮件经过验证
